In the HELIOS-B randomized trial in patients with transthyretin amyloid cardiomyopathy, treatment with the RNA interference agent vutrisiran, which targets transthyretin, led to improved echocardiographic measures of cardiac structure and function, as compared to placebo.
- Karola S. Jering
- Marianna Fontana
- Hicham Skali
